NeuroMab™ Anti-CXCR4 BBB Shuttle Antibody(NRZP-1022-ZP3785)

Figure 1 shows the cross-reactivity of the anti-human CXCR4 antibody h3G10.1.91.A58B to cynomolgus monkey CXCR4 by flow cytometry in a dilution series (0.007-267 nM) against HPB-ALL (human T-cell leukemia) and Cyno- CXCR4-transfected CHO cells were analyzed.

Figure 2 shows the effect of anti-human CXCR4 antibody h3G10.1.91.A58B on Raji (NHL; human non-Hodgkin's lymphoma) and HSC-F (cynomolgus monkey T cell line).

Figure 3 shows the ADCC activity of 12A11, 6B6 and 3G10 anti-human CXCR4 antibodies on Ramos (NHL) cells.

Figure 4 shows a comparison of ADCC activities of m3G10-hlgG1 and m3G10-hlgG4 anti-human CXCR4 antibodies on MOLT-4 (T-acute lymphoblastic leukemia) cells.

Figure 5 shows inhibition of calcium flux by 3G10, 6B6 and 12A11 anti-human CXCR4 antibodies.

Figure 6 shows that 3G10, 6B6 and 12A11 anti-human CXCR4 antibodies significantly inhibited tumor growth in a non-Hodgkin's lymphoma (NHL) model (Ramos) compared to an isotype control antibody.

Figure 7 shows that anti-human CXCR4 antibodies 3G10, 6B6 and 12A11 had a significant effect on tumor burden in animals systemically implanted with Raji-LUC cells compared to an isotype control antibody.

Figure 8 is a survival curve showing the significant effect of anti-human CXCR4 antibodies 3G10, 6B6 and 12A11 compared to an isotype control antibody on the survival of animals systemically implanted with Raji-LUC cells.

Figure 9 shows that humanized anti-human CXCR4 antibody significantly inhibits tumor growth in a non-Hodgkin's lymphoma (NHL) model (Ramos) compared to an isotype control antibody.

Figure 10 shows the significant antitumor effect of CXCR4 ADCs 3G10-TG6-vc0101 and 6B6-TG6-vc0101 in Ramos (NHL) tumor model.

Figure 11 shows the significant anti-tumor effect of CXCR4 ADC 3G10-TG6-vc0101 in HPB-ALL (T-ALL) tumor model.

Figure 12 shows the bioluminescence (fluorescein Enzyme activity) quantification